Perturbations in the intracellular PtdIns 3,5-P 2 pool or the downstream transmission of PtdIns 3,5-P 2 signals often result in a gradual development of gross morphological changes in the pleiomorphic multivesicular endosomes, culminating with the appearance of cytoplasmic vacuoles. To identify the onset of PtdIns 3,5-P 2 functional requirements along the endocytic system, we characterized here morphological changes associated with early expression of the dominant-negative kinase-deficient form (K1831E) of the cytosols had the opposite effect, consistent with PtdIns 3,5-P 2 production negatively regulating the endosome fusion. Together, our data indicate that PtdIns 3,5-P 2 defines specific endosome platforms at the onset of the degradation pathway to regulate the complex process of membrane remodeling and dynamics.
INTRODUCTION
In mammalian cells, proteins and lipids from the cell surface or the Golgi apparatus are sorted to lysosomes for degradation via the endosome membrane system (for recent reviews see Refs. 14, 16, 23, 28, 32, 36, 37) . At the ultrastructural level, the endosomes in the degradation pathway are characterized by the presence of intralumenal membranes with a vesicular and/or lamellar appearance and therefore are referred to as multivesicular endosomes. While arising by a common mechanism of an inward invagination of the limiting membrane, the multivesicular endosomes in the degradation pathway comprise a system of heterogeneous membrane compartments that show significant functional and biochemical differences. Multivesicular bodies (MVBs) are a subset of multivesicular endosomes with characteristics of late endosome/prelysosomal compartments. They arise by detachment from (17) or maturation of early endosomes (37) and function as transport intermediates between early and late endosome compartments; hence the acronym ECV for Endosome Carrier Vesicles (14, 16) (used herein along with MVBs).
The formation of intralumenal endosome membranes is considered to be mechanistically coupled to protein sorting into the MVB pathway (for recent reviews see Refs. 17, 23, 40, 47) . Genetic studies in yeast reveal the requirement for a set of genes, the class E VPS, whose products, assembled in complexes ESCRT-I, -II and -III, consecutively execute the selection of ubiquitylated membrane protein cargoes into the MVB pathway.
A similar mechanism, at least for a subset of down-regulated ubiquitylated receptors, likely operates in mammalian cells, where several ESCRT subunits and interactions have been functionally characterized (1) (2) (3) 51) . In addition, an endosomal COP complex, 4 ARF1, other accessory proteins, as well as lysobisphosphatidic acid (LBPA) have also been implicated in intralumenal vesiculation of mammalian ECV/MVBs or late endosomes (18, 24, 26) , an increased complexity likely reflecting the elaborate heterogeneity of the inward vesiculating endocytic compartments in mammalian cells.
Detachment of ECV/MVBs from early endosomes is thought to use a protein machinery distinct from that required for intralumenal membrane formation, with annexin II characterized as one of multiple unidentified factors that regulate this complex process in mammalian cells (27) .
Studies in both yeast and mammalian cells indicate that in addition to the protein machinery, endosome membrane dynamics and protein sorting require the phosphorylated derivatives of phosphatidylinositol (PtdIns), and particularly PtdIns 3-P and PtdIns 3,5-P 2 (9, 11, 21, 34) . PtdIns 3-P has been localized to membranes of early endosomes and ECV/MVB transport intermediates (13) . Recent studies implicate PtdIns 3-P in membrane receptor sorting and intralumenal vesicle formation but not in the biogenesis of the ECV/MVB transport intermediates in mammalian cells (35) . Less clear is the distribution and the specific role of PtdIns 3,5-P 2 along the endocytic tract.
Antibodies or bio-reporters for PtdIns 3,5-P 2 selective binding and visualization in a cellular context are unavailable or inappropriate to address directly these questions (38) .
The intracellular distribution of PtdIns 3,5-P 2 is therefore inferred from the localization of endogenous or ectopically expressed PIKfyve, the sole enzyme that synthesizes PtdIns 3,5-P 2 from PtdIns 3-P in mammalian cells (reviewed in Ref. 44 ). Because at steady state PIKfyve is largely absent form early/recycling endosomes, defined both biochemically 5 and morphologically, but colocalizes, at least in part, with the late endosome/TGN marker, cation-independent mannose 6-phosphate receptor (MPR) (45) , PtdIns 3,5-P 2 is, presumably, enriched in the later endocytic membranes. That PtdIns 3,5-P 2 also functions along the late endocytic pathway is suggested on the basis of the ability of dominantnegative kinase-deficient PIKfyve mutants to induce dilated vesicles and cytoplasmic vacuoles, some positive for MPR, and to delay the later traffic of solutes (19, 20) .
However, the gross morphological changes induced upon expression of these mutants, together with the heterogeneity of the multivesicular endosomes, make the initial compartment for a PtdIns 3,5-P 2 functional requirement elusive. With the goal to identify the PtdIns 3,5-P 2 
Cell-free endosome fusion assay
In vitro endosome fusion was performed following published protocols (15, 29) . (20, 41, 43, 45) . Co-injected internal HPLC standards were prepared or purchased from sources detailed previously (20, 45) . The radioactivity incorporated was analyzed with an on-line flow scintillation analyzer (Packard, Radiomatic 525TR). The radioactivity of the 32 P-PtdIns 3,5-P 2 peaks was quantified by area integration and is presented as a percentage of total PI radioactivity, as indicated in figure legends. cotransfected with the myc-tagged forms of the two PIKfyve constructs were subjected to immunoprecipitation with the above indicated anti-HA and anti-myc antibodies under previously described conditions (20, 45) . Western blotting was then performed with these antibodies as specified elsewhere (20, 45) .
Immunoprecipitation and immunoblotting

RESULTS
Enlargement of EEA1-and Rab5-positive perinuclear endosomes in early
PIKfyve
K1831E expression
Confocal microscopy studies conducted previously (21, 22) and in this study ( Fig. 1 Crucial for the EEA1 recruitment on early endosomes is the presence of the GTP-binding protein Rab5 (12, 31 , as monitored at early stages of expression, expands the EEA1-or Rab5-positive endosomes at the perinuclear area and largely accumulates on the enlarged structures.
Redistribution of late endosome/lysosome structures in early PIKfyve K1831E expression
To examine the effect of the perturbed PtdIns 3-P-to-PtdIns 3,5-P 2 transition due to PIKfyve K1831E expression on the late endocytic/lysosomal compartments, we next assessed the relationship between the enlarged PIKfyve , vesicles labeled by LAMP1-or Rab7 WT were seen redistributed laterally from the perinuclear region toward the cell periphery in 70-80% of the transfected cells (Fig. 3 , and data not shown). -positive vesicles (Fig. 5) . The reverse was also evident (Fig. 5) mutant at a level 7-fold higher than endogenous PIKfyve, whereas expression of endogenous PIKfyve is comparable to that in the parental cells (41, and data not shown).
As indicated in Fig. 6 -protein expression levels were increased by ~7-fold upon induction compared to endogenous PIKfyve in noninduced cells or parental cells (41) . As illustrated in Figure 8 , cytosol from cells induced to express PIKfyve WT reduced by 25% and 40% the homotypic early-or total endosome fusion, respectively, compared to cytosols from PIKfyve WT -noninduced cells.
By contrast, cytosols from cells expressing PIKfyve K1831E increased the relative efficiency of the early-or total endosome fusion to 140% and 180%, respectively, vs.
cytosol from noninduced PIKfyve K1831E cells (Fig. 8) . Control cytosols from parental cells did not show significant changes in endosome fusion as a function of the cell induction (data not shown).
Attempts were made to evaluate the relative proportion of the homotypic late-endosome fusion by pulse-labeling BHK21 cells with avidin or biotinylated HRP for 5 min followed by additional 25 min of chase, conditions which should label predominantly late endosomes (15, 30) . However, under our conditions, the labeling of late endosomes was too low, likely due to recycling of the markers (15); therefore, measurements of this type
were not further pursued. Together, the data indicate that the endosome fusion efficiency is negatively regulated by a mechanism that involves PIKfyve enzymatic activity and, most likely, PtdIns 3,5-P 2 production.
This notion was further corroborated by results from the cell-free fusion assay utilizing an N-terminal kinase-deficient peptide fragment of PIKfyve, PIKfyve99-473, that harbors the FYVE-finger domain for localization to membrane PtdIns 3-P. Experimental evidence obtained in a transfected cell system is consistent with a displacement of the endogenous PIKfyve from membranes under higher expression levels of the PIKfyve FYVE-finger peptide (42) . As illustrated in Fig. 8 , like the dominant-negative kinasedeficient PIKfyve K1831E mutant, purified GST-PIKfyve99-473 peptide increased the fusion activity of early endosomes. This effect was specific since the GST-PIKfyve99-473Δ177-198 mutant peptide, in which the basic PtdIns 3-P-interacting pocket within the FYVE-finger domain was truncated to abolish membrane association (42), had no effect (Fig. 8 ). Together these data suggest that a PtdIns 3-P targeting mechanism is essential in the PIKfyve-mediated negative regulation of endosome fusion. (Fig. 1) . We monitored cells during the first phase, thus avoiding possible formation of hybrid compartments and other secondary consequences due to acquisition of aberrant cellular architecture. Our studies unequivocally demonstrate that, under perturbed PtdIns 3-P-to-PtdIns 3,5-P 2 conversion due to PIKfyve K1831E expression (Fig. 6) , the kinase-deficient mutant, unlike the wild type enzyme, is largely localized on expanded EEA1-and Rab5-labeled perinuclear endosomes (Fig. 2) . This localization is dependent on the presence of active forms of Rab5 and PI 3-Ks (Fig. 7) , mechanistically consistent with the formation of PtdIns 3-Penriched microdomains by the Rab5-GTP-dependent recruitment of PI 3-kinases (7, 33, 53 -enriched cytosols, as well as a PIKfyve-derived peptide fragment that lacks kinase activity but exhibits the FYVE finger domain for targeting membrane PtdIns 3-P largely increased endosome fusion (Fig. 8) . These data are consistent with the conclusion that the correct endosome organization and dynamics require the PIKfyvecatalyzed PtdIns 3-P-to-PtdIns 3,5-P 2 conversion at early endosomes and that thereby produced PtdIns 3,5-P 2 negatively regulates endosome membrane fusion activity.
DISCUSSION
Place of PIKfyve action and steady-state localization
That PtdIns 3,5-P 2 action is required at early endosomes was quite unexpected since the steady-state distribution of PIKfyve, either the endogenous in 3T3-L1 adipocytes or ectopically expressed in COS and HEK293, largely skip over early/recycling endosomes.
Thus, despite the fact that the FYVE-finger domain directs PIKfyve to associate with PtdIns 3-P (42) and that the early endosomes are enriched in PtdIns 3-P, endogenous
PIKfyve or PIKfyve WT did not biochemically cofractionate with several early/recycling endosome markers such as TfR, IRAP, GLUT4 and Rab4 (43, 45) , nor did they colocalize with the above or here-examined early-endosome markers to a substantial extent as tested by fluorescence microscopy (Fig. 2) . The strong colocalization observed here between the dominant-negative kinase-deficient PIKfyve K1831E mutant and the early endosome markers (Fig. 2 ) is therefore consistent with the kinase activity being important for the PIKfyve exclusion from early endosomes. Concordantly, when coexpressed with the dominant-negative PIKfyve
K1831E
, PIKfyve WT almost exclusively accumulated on the dilated endosome membranes populated by PIKfyve K1831E (Fig. 5) , implying that the potency to convert PtdIns 3-P-to-PtdIns 3,5-P 2 determines the residence time of PIKfyve on early endosomes. Further support for this conclusion comes from our observations with expressed GFP-PIKfyve(1-286) N-terminal peptide fragment that harbors the FYVE-finger domain for PtdIns 3-P association but is kinase inactive (42), which strongly colocalized with endogenous EEA1 in COS cells (Fig. 5) . Furthermore, the early endosome accumulation of PIKfyve appears to rely on the active GTP-bound Rab5 forms and formation of distinct PtdIns 3-P-enriched microdomains on early endosomes as a result of a Rab5-GTP-dependent recruitment of PI 3-Ks (7, 33, 53) . This is evidenced here by documenting a diffuse staining for PIKfyve WT and PIKfyve K1831E under expression of the GDP-loaded Rab5a S34N mutant but a strong wortmannin-dependent recruitment of both PIKfyve K1831E and PIKfyve WT to the Rab5a Q79L -dilated endosome structures in the presence of expressed GTPase-deficient mutant (Fig. 7) . Together, these data support a model whereby the PtdIns 3-P microdomain at early endosomes represents a major entry site for the cytosolic pool of PIKfyve. Driven by its catalytic activity, PIKfyve is then rapidly retrieved from early endosomes to later compartments by a mechanism that involves local membrane remodeling in two ways, by decreasing PtdIns 3-P and increasing PtdIns 3,5-P 2 . The fact that PIKfyve WT is largely visualized on endosomes positive for Rab5a Q79L could be due to abnormally high PtdIns 3-P-to-PtdIns 3,5-P 2 ratio as a result of enhanced recruitment of PI 3-Ks and, presumably, the PtdIns 3,5-P 2 -phosphatases of the myotubularin family that display a FYVE finger for PtdIns 3-P binding (25) .
One important but still unresolved question in the present study is the nature of the later compartments of PIKfyve membrane retrieval predicted here, which most likely are the principal residence place of steady state PIKfyve. Membrane association of PIKfyve is entirely dependent on PtdIns 3-P, indicated by the diffuse PIKfyve WT staining upon cell treatment with wortmannin (42, and this study) or upon expression of dominant-negative Rab5 S34N (Fig. 7) . Because PtdIns 3-P, besides in the nucleus, is almost exclusively localized along the early-late endosomal system (13), membrane PIKfyve should be entirely found on endocytic structures. However, while colocalizing to some degree with a variety of markers for generic late endosomes/lysosomes, such as MPR (45) have distinct yet unidentified protein and lipid compositions (14, 16, 17, 40) , are logical candidates harboring a subfraction of membrane PIKfyve at steady state. It is tempting to speculate that the PIKfyve-catalyzed PtdIns 3,5-P 2 remodeling at distinct regions of early endosomes is part of still unidentified mechanisms for a correct formation of free ECV/MVB transport intermediates through detachment from early endosomes.
Consistent with this hypothesis are the observations here and in our previous studies for dispersed, sometimes enlarged, late endosomes, and a kinetic delay in early-to-late endosome traffic (19, and Fig. 3) . As appropriate markers and probes for the ECV/MVBs and PtdIns 3,5-P 2 become available, we believe this hypothesis could be directly tested.
PtdIns 3,5-P 2 in endosome fusion
One of the major defects associated with expression of dominant-negative kinase deficient PIKfyve K1831E and, therefore, a PtdIns 3,5-P 2 deficiency, is dilated endosome structures and vacuole formation, posing the central question as to how this excess membrane is provided. Theoretically, the increased size of EEA1-or Rab5-positive perinuclear early endosomes under PIKfyve K1831E expression could have been resulting from either increased early endosome fusion, perturbation in the mechanisms of the ECV/MVB transport intermediates' detachment/maturation from early endosomes, or both. In this study we have directly tested the in vitro endosome fusion and obtained unequivocal evidence that the additional membrane due to PIKfyve K1831E expression is provided, at least in part, by an increased endosome fusion efficiency. Our data demonstrating that PIKfyve K1831E cytosols as well as a PIKfyve fusion peptide fragment that retains PtdIns 3-P membrane targeting signal but is kinase inactive, displayed an enhanced capacity to complement the in vitro early endosome fusion, whereas the PIKfyve WT cytosols had the opposite effect (Fig. 8 ), are consistent with the idea that PtdIns 3,5-P 2 , directly or indirectly, regulates negatively the endosome fusion rate. This effect seems to not be restricted to early stages of the pathway. Our observations rather suggest that PIKfyve enzymatic activity is also involved in the mechanism that controls fusion steps in later compartments, although their precise identity was not determined in this study. Among others, these may include the intralumenal membrane fusion with the limiting membrane of multivesicular endosomes, which has been predicted to occur in mammalian cells (26, 48) . Such a role for PIKfyve and PtdIns 3,5-P 2 would be consistent with data from our transmission electron microscopy studies in a HEK293 stable cell line expressing dominant-negative PIKfyve K1831E , demonstrating that whereas intralumenal endosome vesicles could be readily seen in dilated MVB-like structures, they are low in number vs. similar structures in control cells (19) . It is conceivable that PtdIns 3,5-P 2 is required to negatively regulate the rate of fusion at more than one place among the heterogeneous multivesicular endosomes, thus contributing to the dynamic properties of these membranes. 
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